Identification of Prostate Cancer Specific Markers in Patients Compared to Healthy Participants

Prostatic Neoplasms Clinical Trial

Official title: Identification and Characterization of Commercial RUO Antibodies for the Detection of Specific Prostate Cancer Tumoral Markers Expressed in Potential Circulating Tumoral Cells (CTCs)

Status Recruiting

Clinical Trial Summary

This is an exploratory research study with the aim of identifying specific cancer biomarkers in various subtypes of prostate cancer. Blood samples will be collected from 60 participants divided into 40 patients and 20 healthy donors.

Clinical Trial Description

In this research study different commercial RUO (Research Use Only) antibodies will be purchased and then tested on blood samples obtained by patients affected by prostate cancer and by healthy participants as control. Sixty participants will be enrolled belonging to different risk categories:20 participants affected by prostate cancer at low risk, 20 participants affected by prostate cancer at high risk, and 20 participants without a cancer disease (healthy volunteers) as control. Risk categorization is based on the definition of the European Association of Urology. After signing the informed consent form, participants will be screened to evaluate if they meet the eligibility criteria. If all the criteria are met, participants will be enrolled into the study and will be asked to provide some demographic and other data. A 13 ml blood sample will be collected by the participants and shipped to Sponsor's laboratories, in order to be processed and analysed. ;

Related Conditions & MeSH terms

• Prostatic Neoplasms

• NCT number: NCT04964271
• Study type: Observational
• Source: Tethis S.p.A.
• Contact: Vito Cucchiara, MD
• Phone: +390226436923
• Email: cucchiara.vito@hsr.it
• Status: Recruiting
• Start date: September 9, 2021
• Completion date: July 2023